Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
← catalyst calendarNCT07685808 · readout in 519 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
360estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-29 | estimated | When the study began enrolling |
| Primary completion | 2028-01-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-21 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Overweight or Obesity
Interventions
- Drug: Olatorepatide — also filed as HS-20094
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to approximately 60 weeks
Severity of TEAEs
measured Up to approximately 60 weeks
Percent change in body weight
measured From baseline to week 52
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed